157 related articles for article (PubMed ID: 35392152)
1. Diagnostic Value of Dynamic Enhanced Magnetic Resonance Imaging Combined with Serum CA15-3, CYFRA21-1, and TFF1 for Breast Cancer.
Xue F; Meng Y; Jiang J
J Healthc Eng; 2022; 2022():7984591. PubMed ID: 35392152
[TBL] [Abstract][Full Text] [Related]
2. Clinical value of CYFRA21-1, NSE, CA15-3, CA19-9 and CA125 assay in the elderly patients with pleural effusions.
Li CS; Cheng BC; Ge W; Gao JF
Int J Clin Pract; 2007 Mar; 61(3):444-8. PubMed ID: 17313612
[TBL] [Abstract][Full Text] [Related]
3. [Clinical value of tumor-associated autoantibodies in diagnosis of early non-small cell lung cancer].
Ren Z; Ding HM; Qian X; Pan SY
Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Dec; 55(12):1426-1434. PubMed ID: 34963239
[No Abstract] [Full Text] [Related]
4. Assessment of Seven Clinical Tumor Markers in Diagnosis of Non-Small-Cell Lung Cancer.
Chen ZQ; Huang LS; Zhu B
Dis Markers; 2018; 2018():9845123. PubMed ID: 30647803
[TBL] [Abstract][Full Text] [Related]
5. Dynamic Enhanced Magnetic Resonance Imaging versus Ultrasonic Diffused Optical Tomography in Early Diagnosis of Breast Cancer.
Xue F; Jiang J
J Healthc Eng; 2022; 2022():4834594. PubMed ID: 35449832
[TBL] [Abstract][Full Text] [Related]
6. The Clinical Significance of sICAM-1 in Differentiating Benign Breast Lesions from Breast Cancer.
Chen C; Chen Q; Dong Y; Liu X
Ann Clin Lab Sci; 2020 Sep; 50(5):650-656. PubMed ID: 33067211
[TBL] [Abstract][Full Text] [Related]
7. Fine-needle aspirates CYFRA 21-1 is a useful tumor marker for detecting axillary lymph node metastasis in breast cancer patients.
Yoon JH; Han KH; Kim EK; Moon HJ; Kim MJ; Suh YJ; Choi JS; Park BW
PLoS One; 2013; 8(2):e57248. PubMed ID: 23451192
[TBL] [Abstract][Full Text] [Related]
8. The Serum Tumor Markers in Combination for Clinical Diagnosis of Lung Cancer.
Wu H; Wang Q; Liu Q; Zhang Q; Huang Q; Yu Z
Clin Lab; 2020 Mar; 66(3):. PubMed ID: 32162867
[TBL] [Abstract][Full Text] [Related]
9. Comparison of serum tumor markers combined with dual-source CT in the diagnosis of lung cancer.
Shan Y; Yin X; Zhao N; Wang J; Yang S
Minerva Med; 2023 Dec; 114(6):795-801. PubMed ID: 33764713
[TBL] [Abstract][Full Text] [Related]
10. CA15-3 is a useful serum tumor marker for diagnostic integration of hybrid positron emission tomography with integrated computed tomography during follow-up of breast cancer patients.
Incoronato M; Mirabelli P; Catalano O; Aiello M; Parente C; Soricelli A; Nicolai E
BMC Cancer; 2014 May; 14():356. PubMed ID: 24886519
[TBL] [Abstract][Full Text] [Related]
11. FTO, PIK3CB serve as potential markers to complement CEA and CA15-3 for the diagnosis of breast cancer.
Mi J; Zhang H; Cao W; Yuan C
Medicine (Baltimore); 2023 Oct; 102(42):e35361. PubMed ID: 37861518
[TBL] [Abstract][Full Text] [Related]
12. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic Value and Clinical Significance of Combined Detection of Serum Markers CYFRA21-1, SCC Ag, NSE, CEA and ProGRP in Non-Small Cell Lung Carcinoma.
Li Q; Sang S
Clin Lab; 2020 Nov; 66(11):. PubMed ID: 33180443
[TBL] [Abstract][Full Text] [Related]
14. The Application Value of Serum HE4 in the Diagnosis of Lung Cancer.
Wang Y; Wang Z; Ding Y; Sun F; Ding X
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2405-2407. PubMed ID: 31450913
[TBL] [Abstract][Full Text] [Related]
15. Could the serial determination of Ca15.3 serum improve the diagnostic accuracy of PET/CT?: results from small population with previous breast cancer.
Evangelista L; Baretta Z; Vinante L; Cervino AR; Gregianin M; Ghiotto C; Bozza F; Saladini G
Ann Nucl Med; 2011 Aug; 25(7):469-77. PubMed ID: 21476056
[TBL] [Abstract][Full Text] [Related]
16. Preoperative predicting malignancy in breast mass-like lesions: value of adding histogram analysis of apparent diffusion coefficient maps to dynamic contrast-enhanced magnetic resonance imaging for improving confidence level.
Liu HL; Zong M; Wei H; Lou JJ; Wang SQ; Zou QG; Shi HB; Jiang YN
Br J Radiol; 2017 Nov; 90(1079):20170394. PubMed ID: 28876982
[TBL] [Abstract][Full Text] [Related]
17. The reference intervals for CA125, CA15-3, CA19-9, CA72-4, AFP, CEA, NSE and CYFRA21-1.
Yang J; Tang A; Ma J; Sun X; Ming L
Scand J Clin Lab Invest; 2019; 79(1-2):71-74. PubMed ID: 30727773
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer.
Gion M; Mione R; Leon AE; Dittadi R
Clin Chem; 1999 May; 45(5):630-7. PubMed ID: 10222349
[TBL] [Abstract][Full Text] [Related]
19. [Application of serum proteomic mass spectrum analysis in breast cancer].
Ying MG; Chen Q; Ye YB; Chen HJ; Chen X; Zheng HY; Wu F
Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):698-702. PubMed ID: 21122387
[TBL] [Abstract][Full Text] [Related]
20. Retrospective analysis of the utility of multiparametric MRI for differentiating between benign and malignant breast lesions in women in China.
Fan WX; Chen XF; Cheng FY; Cheng YB; Xu T; Zhu WB; Zhu XL; Li GJ; Li S
Medicine (Baltimore); 2018 Jan; 97(4):e9666. PubMed ID: 29369183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
